July 16th 2020
By Tony Hagen
An upcoming webinar from MJH Life Sciences™ will address the payer rebate deals that limit provider choice of biosimilars and complicate clinical pharmacy operations.
By Deana Ferreri, PhD
Wide variation in treatment patterns for Crohn disease is attributable to failures to translate evidence uniformly and cost barriers. Authors of a new report have formulated algorithms to help reduce heterogeneity in treatment of patients.
July 7th 2020
Slow growth of use of biosimilar infliximab in a Medicare fee-for-service population suggests lingering hesitancy on the part of gastroenterologists and patients, particularly when it comes to extrapolation to off-label uses, according to a new study.
June 24th 2020
By Allison Inserro
The UK results show how challenging switching to a biosimilar can be, according to patient groups.
May 10th 2020
With successful findings from a phase 3 trial of its bevacizumab biosimilar candidate, Iranian company AryoGen Pharmed is a step closer to commercialization of this product.
May 7th 2020
The Federal Trade Commission was deeply divided over whether the AbbVie-Allergan $63 billion merger plan would allow for a sufficiently competitive marketplace.
May 6th 2020
Although the totality of the evidence is reassuring, the jury is still out on nonmedical switching to biosimilars, according to new study results.
April 11th 2020
The Danish medical system saved 82.8% on adalimumab by switching almost all patients from the reference product to biosimilars, but such a benefit for the US healthcare system may not be possible, according to a new study.
April 7th 2020
In inflammatory bowel diseases (IBD), biosimilars have been available for roughly 5 years, but more evidence may be necessary to persuade medical community to increase usage, according to a study.
March 31st 2020
Canadian provinces encounter opposition in their move to implement forced switching of patients from reference products to biosimilars.
